TECHNOLOGY

Scientific Publications and Presentations
 
Journal Publications

  • Ramakrishnan, B et al. A Structural and Mathematical Modeling Analysis of the Likelihood of Antibody-Dependent Enhancement in Influenza. Trends Microbiol. [Epub ahead of print] (2016)
  • Baranovich, T et. al. The Hemagglutinin Stem-Binding Monoclonal Antibody VIS410 Controls Influenza Virus-Induced Acute Respiratory Distress Syndrome. Antimicrob Agents Chemother. 60:2118-31. (2016)
  • Wollacott, AM et. al. Safety and Upper Respiratory Pharmacokinetics of the Hemagglutinin Stalk-Binding Antibody VIS410 Support Treatment and Prophylaxis Based on Population Modeling of Seasonal Influenza A Outbreaks. EBioMedicine. 5:147-55. (2016)
  • Shriver, Z; Trevejo, JM; Sasisekharan R. Antibody-Based Strategies to Prevent and Treat Influenza. Front Immunol. 6:315. (2015)
  • Tharakaraman K, et al. A broadly neutralizing human monoclonal antibody is effective against H7N9 . PNAS. 112(35):10890–95. (2015)
  • Robinson L, et al. Structure-Guided Design of an Anti-dengue Antibody Directed to a Non-immunodominant Epitope. Cell. 162(3):493–504. (2015)
  • Viswanathan K, et al. Amino acid interaction networks provide a new lens for therapeutic antibody discovery and anti-viral drug optimization. Current Opinion in Virology. 11:122–129. (2015)
  • Tharakaraman K, et al. Glycan receptor binding of the influenza A virus H7N9 hemagglutinin. Cell. 153(7):1486-93. (2013)
  • Tharakaraman K, et al. Structural determinants for naturally evolving H5N1 hemagglutinin to switch its receptor specificity. Cell. 153(7):1475-85. (2013)
  • Artpradit C, et al. Recognition of heparan sulfate by clinical strains of dengue virus serotype 1 using recombinant subviral particles. Virus Res. 176(1-2):69-77. (2013)
  • Tharakaraman K, et al. Antigenically intact hemagglutinin in circulating avian and swine influenza viruses and potential for H3N2 pandemic. Sci Rep. 3:1822. (2013)
  • Srinivasan K, et al. Quantitative characterization of glycan-receptor binding of H9N2 influenza A virus hemagglutinin. PLoS One. 8(4):e59550. (2013)
  • Hobbie SN, et al. Modular glycosphere assays for high-throughput functional characterization of influenza viruses. BMC Biotechnol. Apr 15;13:34. (2013)
  • Tharakaraman K, et al. Redesign of a cross-reactive antibody to dengue virus with broad-spectrum activity and increased in vivo potency. Proc Natl Acad Sci USA. 110(17):E1555-64. (2013)
  • Srinivasan K, et al. Quantitative description of glycan-receptor binding of influenza A virus H7 hemagglutinin. PLoS One. 8(2):e49597. (2013)
  • Jayaraman A, et al. Glycosylation at Asn91 of H1N1 haemagglutinin affects binding to glycan receptors. Biochem J. 444(3):429-35. (2012)
  • Soundararajan V, et al. Networks link antigenic and receptor-binding sites of influenza hemagglutinin: mechanistic insight into fitter strain propagation. Sci Rep.;1:200. (2011)
  • Aich U, et al. Glycomics-based analysis of chicken red blood cells provides insight into the selectivity of the viral agglutination assay. FEBS J. 278(10):1699-712. (2011)
  • Jayaraman A, et al. A single base-pair change in 2009 H1N1 hemagglutinin increases human receptor affinity and leads to efficient airborne viral transmission in ferrets. PLoS One. 6(3):e17616. (2011)
  • Viswanathan K, et al. Determinants of glycan receptor specificity of H2N2 influenza A virus hemagglutinin. PLoS One. 5(10):e13768. (2010)
  • Viswanathan K, et al. Glycans as receptors for influenza pathogenesis. Glycoconj J. 27(6):561-70. (2010)
  • Pappas C, et al. Receptor specificity and transmission of H2N2 subtype viruses isolated from the pandemic of 1957. PLoS One. Jun 21;5(6):e11158. (2010)
  • Soundararajan V, et al. Atomic interaction networks in the core of protein domains and their native folds. PLoS One. Feb 23;5(2):e9391. (2010)
  • Hensley SE, et al. Hemagglutinin receptor binding avidity drives influenza A virus antigenic drift. Science. 326(5953):734-6. (2009)
  • Shriver Z, et al. Context-specific target definition in influenza a virus hemagglutinin-glycan receptor interactions. Chem Biol. Aug 28;16(8):803-14. (2009)
  • Maines TR, et al. Transmission and pathogenesis of swine-origin 2009 A(H1N1) influenza viruses in ferrets and mice. Science. 325(5939):484-7. (2009)
  • Soundararajan V, et al. Extrapolating from sequence--the 2009 H1N1 'swine' influenza virus. Nat Biotechnol. 27(6):510-3. (2009)
  • Srinivasan A, et al. Quantitative biochemical rationale for differences in transmissibility of 1918 pandemic influenza A viruses. Proc Natl Acad Sci USA. 105(8):2800-5. (2008)
  • Chandrasekaran A, et al. Glycan topology determines human adaptation of avian H5N1 virus hemagglutinin. Nat Biotechnol. 26(1):107-13. (2008)
Conference Presentations

  • VIS649: a Highly Potent Anti-APRIL Antibody for the Treatment of IgA Nephropathy. J. Myette, H. Adari, G. Babcock, K. Deotale, K. Viswanathan, A. Wollacott. American Society of Nephrology. November 2016.
  • Antibody-Based Approaches for Prophylaxis and Treatment of Zika Virus. J Trevejo. WHO and Wellcome Trust Meeting – Mosquito-Borne Viruses: Can We Build on Commonalities to Pre-empt the Future? Oct 2016.
  • Anti-Influenza Antibody VIS410 Targets a Broadly Conserved Epitope on Hemagglutinin. K. Viswanathan, S. Sloan, A. Wollacott, K. Szretter, G. Babcock. October 2016.
  • Evaluation of Efficacy and Emergence of Resistance to VIS410, a Human Monoclonal Antibody, in a Human Challenge Model of Infection with a p2009 H1N1 Virus. S Sloan, GJ Babcock, K Szretter, S Bedard, C Hay, J Williams, E Hershberger, J Trevejo. Options for the Control of Influenza IX. Aug 2016.
  • VIS410 Monoclonal Antibody Demonstrates Potent Efficacy Against Neuraminidase Inhibitors-Susceptible and -Resistant Influenza A (H7N9) Viruses and Protects Mice from Development of ARDS. T Baranovich, J Jones, S Sloan, K Szretter, J Trevejo, P Seiler, R Webby, E Govorkova. ISIRV-AVG Novel Antiviral Therapies for Influenza and other Respiratory Viruses: Bench to Bedside. June 2015.
  • VIS410, a Broadly Neutralizing Antibody to Influenza A: Characterisation and Potential for ADE. J Trevejo. ISIRV-AVG Novel Antiviral Therapies for Influenza and other Respiratory Viruses: Bench to Bedside. June 2015.
  • Development of Immunological Countermeasures for Zika Virus. L. Robinson. Bridging the Sciences: Zika Virus. May 2016.
  • Monoclonal Antibody Products for Infectious Diseases. K. Viswanathan. Americas Antibody Congress May 2016.
  • Review of Antibody-Based Approaches to Prophylaxis and Treatment of Zika Virus. L Robinson, A Wollacott, G Babcock, Z Shriver, J Trevejo. 5th Pan-American Dengue Research Network Meeting. April 2016.
  • Improved Antibody Docking Using Knowledge Based Approaches. A. Wollacott, B. Ramakrishnan, L. Robinson, G. Babcock, Z. Shriver, K. Viswanathan. Antibody Engineering and Therapeutics Conference. December 2015.
  • Structure Guided Design of a Potent Anti-Dengue Antibody. L. Robinson, K. Rowley, A. Winnett, B. Ramakrishnan, A. Wollacott, K. Viswanathan, J. Myette, G. Babcock, Z. Shriver. Antibody Engineering and Therapeutics Conference. December 2015.
  • Design of a Broadly Neutralizing Antibody Targeting Dengue Virus E Protein Domain III. L. Robinson, J. Myette, K. Viswanathan, Z. Shriver, G. Babcock. Courage Foundation Conference. December 2015.
  • VIS410, a HA-Targeted Human Antibody, Broadly Neutralizes Influenza Isolates with Pandemic Potential. Y. Budigi, K. Viswanathan, G. Babcock, Z. Shriver. Courage Foundation Conference. December 2015.
  • Engineering of a Full Spectrum Potent Antibody for the Treatment of Dengue. L. Robinson, K. Rowley, T. Koch, H. Tissire, A. Winnett, K. Viswanathan, J. Myette, Z. Shriver, G. Babcock. American Society of Tropical Hygiene Medicine. October 2015.
  • Identification of Epitopes for the Development of Selective, Functional Antibodies Targeting Sodium Ion Channels. G. Babcock, L. Robinson, N. Boatright, B. Ramakrishnan, K. Rowley, J. Kuniholm, K. Teichert, A. Wollacott , K. Viswanathan and Z. Shriver. Discovery on Target. September 2015.
  • VIS410, a Human Antibody, Broadly Neutralizes Both Group 1 and Group 2 Influenza Viruses. G. Babcock. 3rd Influenza Research and Development Conference. July 2014.
  • VIS410, a broadly HA-targeting human antibody, neutralizes H5 and H7 isolates with pandemic potential. G Babcock, K Szretter, S Sloan, K Rowley, S Himansu, K Viswanathan, L Robinson, D Barnard, D Ambrosino, Z Shriver. ICAAC. Sep 2013.
  • VIS410, a Human Antibody, Provides Additive Efficacy when Dosed with Ostelamivir in a Severe Influenza Model. D Ambrosino, S Sloan, G Babcock, K Viswanathan, D Barnard, Z Shriver. Options for the Control of Influenza VIII. Sep 2013.
  • Therapeutic or prophylactic treatment with an HA-stem antibody (VIS410) limits respiratory droplet transmission of influenza virus in the ferret model. S Lakdawala, M Baz, E Lamirande, S Sloan, K Szretter, K Viswanathan, D Ambrosino, K Subbarao. Options for the Control of Influenza VIII. Sep 2013.
  • Design of a Broadly Neutralizing Antibody Targeting Influenza. D Ambrosino, Z Shriver, K Viswanathan. ISIRV Severe Influenza: Burden, Pathogenesis and Management. Oct 2012.
  • Identification and Characterization of Broadly Neutralizing Antibodies Influenza. Z Shriver and K Viswanathan. ID WEEK. Oct 2012.
  • Design of a Broadly Neutralizing Antibody Targeting Influenza A. Z Shriver and K Viswanathan. ICAAC. Sep 2012.
Visterra, Inc. | One Kendall Square, Suite B3301 | Cambridge, MA 02139 | 617-498-1070 | © 2017 Visterra, Inc. All Rights Reserved.